Tuesday, July 29, 2014 6:37:19 PM
Question still remains how could he say he believes they would be in BASI if there wasn't the need for so much material, and then the next day say they are delayed due to diverting material to other labs? If he knew they were diverting material to other labs, then he knew they couldn't be doing BASi testing yet.
Question:
Hello Dr. Seymour,
If I may bother you once again, can you clarify something for me please. You said that had the 'cides not been so safe, you would already be in BASI testing, saying that you needed way more of the material than originally expected. (a very good thing BTW). But then the next day said you were delayed in doing TOX because you had to divert material for additional contract testing (MERS, Dengue…).
My question is which one is true?
If you could clarify, that would help settle much of the hubbub over on ihub. Maybe that's where the word hubbub came from!
Dr. Seymour:
They’re both correct
We had to make 5X as much material as we anticipated because of unbelievable safety AND we had additional demands from the British for H7N9 and MERS and from University of California Berkeley for dengue and from N.E.Ohio University College of Medicine for more herpes mawterial.
And at the same time we’re doing the scale-up
It’s all good!
Space and personnel limitations in the old lab are slowing us down
The new facility will dramatically increase the throughput!
The SwingTrade Portfolio is up 28.3% YTD through 5/30/2014, 83.5% in 2013, and 475.5% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102716798
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM